Bitcoin steigt nach dem Halving wieder über 9‘000 Franken. Jetzt Bitcoin handeln! -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
08.05.2018 22:15:00

Intermolecular Reports First Quarter 2018 Financial Results

Intermolecular Reports First Quarter 2018 Financial ResultsCompany Achieves Third Consecutive Quarter of Positive Adjusted EBITDAPR NewswireSAN JOSE, Calif., May 8, 2018SAN JOSE, Calif., May 8, 2018 /PRNewswire/ -- Intermolecular, Inc. (NASDAQ:IMI), the trusted partner for advanced materials innovation, today reported results for its first quarter ended March 31, 2018.Q1 2018 Financial and Operational HighlightsTotal revenue of $9.7 million, a decrease of 8% over the prior quarter and 3% over the same period last year.Program revenues grew 5% sequentially and 36% over the same period last year.First quarter adjusted EBITDA of $1.0 million (10% of revenue), compared with an adjusted EBITDA loss of $(1.9) million in the same period last year.Total cash and investments increased $1.4 million sequentially to $27.2 million.Secured two new contracts during the quarter.Management Commentary"The first quarter of 2018 marked Intermolecular's third consecutive period of positive adjusted EBITDA, a consistency not seen since 2013," said company president and CEO, Chris Kramer. "Our improved financial performance is the result of the actions we have taken over the past year to both increase customer engagements and reduce our cost structure.  Specifically, on a year-over-year basis, we increased program services revenue by $2.4 million, or 36% in the quarter, while reducing operating expenses by $4.5 million.  This combination has more than offset the planned expiration of royalties from legacy programs and is key for sustainable profitability.  Our engagements with both existing and new customers continue to expand and we remain confident in our ability to continue to grow and scale our business profitably." First Quarter Fiscal 2018 ResultsRevenue for the first quarter of 2018 was $9.7 million, down 8% compared to $10.5 million in the fourth quarter of 2017, and down 3% compared to $9.9 million in the same period a year ago. Program revenues of $9.3 million grew 5% sequentially and 36% over the same period a year ago.Net loss for the first quarter of 2018 was $(0.6) million, or $(0.01) per share, compared to net income of $0.1 million, or $0.00 per share, in the fourth quarter of 2017, and net loss of $(5.8) million, or $(0.12) per share, in the same period a year ago. Non-GAAP net loss for the first quarter of 2018 was $(0.4) million, or $(0.01) per share, compared to non-GAAP net income of $0.4 million, or $0.01 per share, in the prior quarter, and non-GAAP net loss of $(5.2) million, or $(0.10) per share, in the same period a year ago.  Adjusted EBITDA for the first quarter of 2018 was $1.0 million, compared to $2.1 million in the prior quarter, and an adjusted EBITDA loss of $(1.9) million in the same period a year ago.  Cash and investments were $27.2 million at the end of first quarter of 2018, an increase of $1.4 million compared to $25.8 million at the end of fourth quarter of 2017. The company had no debt at quarter end.    Second Quarter of 2018 OutlookThe following statements are based on Intermolecular's current expectations for the second quarter ending June 30, 2018. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below. Intermolecular does not plan to update, nor does it undertake any obligation to update, this outlook in the future.Revenue is projected to be in the range of $9.8 million to $10.2 million;Net income is projected to be between a loss of $(0.3) million, or $(0.01) per share, and a profit of $0.3 million, or $0.01 per share, based on approximately 49.6 million shares expected to be outstanding;Non-GAAP net income, excluding stock-based compensation expense, is projected to be between breakeven and $0.6 million, or between $0.00 to $0.01 per share based on 49.6 million shares expected to be outstanding; and,Adjusted EBITDA is projected to be between $1.2 million and $1.7 million.Intermolecular reports revenue, cost of revenue, gross margin, operating income (loss), net income (loss) and earnings (loss) per share in accordance with U.S. generally accepted accounting principles (GAAP) and additionally on a non-GAAP basis. A reconciliation of the non-GAAP financial measures with the most directly comparable GAAP measures, as well as a description of the items excluded from the non-GAAP measures, is included in the financial statements portion of this press release. Please refer to "Reconciliation of GAAP to Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Income/Loss to Non-GAAP Net Income" below.Conference Call Intermolecular will host a conference call and simultaneous audio-only webcast today (May 8, 2018) at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss these results. The call will be hosted by Intermolecular President and CEO Chris Kramer and CFO Bill Roeschlein.U.S. dial-in number: (877) 251-1860International dial-in number: (224) 357-2386Conference ID: 2183689Please call the conference telephone number five to ten minutes prior to start time. An operator will register your name and organization. If you have difficulty connecting with the conference call, please contact Liolios Group at (949) 574-2386A live and archived webcast (audio only) of the call will be available on Intermolecular's website for up to 30 days after the call.About Intermolecular, Inc.Intermolecular® is the trusted partner for advanced materials innovation. Advanced materials are at the core of innovation in the 21st century for a wide range of industries including semiconductors, consumer electronics, automotive and aerospace. With its substantial materials expertise; accelerated learning and experimentation platform; and information and analytics infrastructure, Intermolecular has a ten-year track record helping leading companies accelerate and de-risk materials innovation. Learn more at  "Intermolecular" and the Intermolecular logo are registered trademarks; all rights reserved. Forward-Looking StatementsStatements made in this press release and the earnings call referencing the press release that are not statements of historical fact are forward-looking statements. Forward-looking statements are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "expects," "believes," "plans," "intends," "projects" and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this document are based on current beliefs, assumptions and expectations, speak only as of the date of this document and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and generally beyond Intermolecular's control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: our ability to productize our workflows with existing and future customers; expectations regarding our future revenue, cash flow and GAAP and non-GAAP net income or loss; financial condition; the ability of our new business model to generate profits and long-term shareholder returns; the extent to which technology developed in collaboration with our customers will continue to remain on the critical path and have significant value for such customers and us as well as the industry as a whole; and anticipated growth in our current markets through expansion of existing customer programs and the entry into other engagements with new customers. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: our ability to execute on our strategy, prove our business model and remain technologically competitive in rapidly evolving industry conditions; commercial acceptance of our HPC platform and methodology as effective R&D tools; our ability to achieve and sustain profitability; the ability of our customers to achieve their announced product roadmaps in a timely manner; the extent to which we are able to successfully extend and expand relationships with existing customers; our ability to manage the growth of our business; the rapid technology changes and volatility of the customers and industries we serve; our potential need for future capital to finance our operations; and other risks described in our most recent annual report on Form 10-K as updated by our quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission available at, particularly in the sections titled "Risk Factors." All forward-looking statements are based on management's current estimates, projections and assumptions, and we assume no obligation to update them.Non-GAAP Financial MeasuresTo supplement the financial data presented on a GAAP basis, we also disclose certain non-GAAP financial measures, which exclude the effect of stock-based compensation expense. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than non-GAAP financial information disclosed by other companies. These results should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. We believe that our non-GAAP financial information provides useful information to management and investors regarding financial and business trends relating to our financial condition and results of operations because the non-GAAP measures exclude charges that management considers to be outside of Intermolecular's core operating results. We believe that the non-GAAP measures of revenue, cost of net revenue, gross profit, gross margin, operating (loss) income, net (loss) income, earnings per share and net (loss) income per share, viewed in combination with our financial results calculated in accordance with GAAP, provide investors with additional perspective and a more meaningful understanding of our ongoing operating performance. In addition, management uses these non-GAAP measures to review and assess financial performance, to determine executive officer incentive compensation and to plan and forecast performance in future periods. Intermolecular, Inc.Condensed Consolidated Statements of Operations(In thousands, except share and per share amounts, Unaudited)Three Months Ended March 31,20182017Revenue:Program revenue$9,256$6,812Licensing and royalty revenue4193,133Total revenue9,6759,945Cost of revenue:Cost of program revenue3,3752,697Cost of licensing and royalty revenue1290Total cost of revenue3,3762,987Gross profit6,2996,958Operating expenses:Research and development4,0327,108Sales and marketing7961,481General and administrative2,2863,008Restructuring charges—1,348Total operating expenses7,11412,945Full story available on
Weiter zum vollständigen Artikel bei "Benzinga"